Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Stoke Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$29.82

+0.46 (+1.57%)

D 31Pipeline Score Richly Valued Biotech · Commercial
Market Cap
1.83 B
EPS
-2.84
P/E Ratio
-
Value Trade
13.13 M
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • Revenue

    6.23 M

  • R&D Expenses

    39.67 M

  • Operating CF

    -60.58 M

  • Total Assets

    443.28 M

  • Total Liabilities

    48.40 M

  • Equity

    394.88 M

  • D/E Ratio

    12,345

-5.48 %
Week
-18.82 %
1 Month
-14.36 %
3 Month
5.46 %
6 Month
-21.3 %
5 Year
7.83 %
All Time
Cash Data
Stable

  • Cash Position

    343.54 M

  • Monthly Burn

    20.19 M

  • Runway

    15.9 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 7, 2026
Overview
Volume
478.90 K
52 Week Range
9.09 - 40.22
% held by Insiders
20.99 %
% held by Institutions
107.12 %
Enterprise Value
1.49 B
Total Shares
57.14 M
Short %
22.85 %
Float Shares
49.14 M
Company Description
HQ: 45 WIGGINS AVENUE, BEDFORD, MA...
Employees:170
https://www.stoketherapeutics....

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 3 data readout example
Phase 3
—
RNA-Based Therapies
Nervous System
Phase 3
—
RNA-Based Therapies
Nervous System
Phase 3
—
RNA-Based Therapies
Nervous System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D31
Pipeline Score
$54M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.0x
rNPV / MCap
Top 34%
Micro Cap
(rank 598 of 905)
Percentile Rank
Stoke Therapeutics, Inc. faces pipeline headwinds (31/100), with $145M risk-adjusted pipeline value, led by Milrinone in Valvular Stenosis (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Milrinone
Small molecule		Valvular StenosisPhase 2NCT008193779% $119M COMPLETED 124 - -Dec 1, 2012 -Oct 25, 2013
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Zorevunersen
Dravet syndrome
Phase 3
2025-07-10
Zorevunersen
Dravet syndrome
Phase 3
2025-07-10
Zorevunersen
Dravet syndrome
Phase 3
2025-07-10
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in STOK
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
STOK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STOK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STOK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
STOK Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
STOK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Stoke Therapeutics, Inc. (STOK) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How STOK ranks across every disease it competes in
No competitive intelligence available for STOK.